ATLANTA, GA – (NewMediaWire) – June 28, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that an abstract regarding GeoVaxâs gene therapy candidate, Gedeptin, has been selected for poster presentation at the American Association for Cancer Research…Read More
GeoVax Announces GedeptinR Presentation at the AACRAHNS Head and Neck Cancer Conference
